Novartis agreed to acquire Pikavation Therapeutics for up to $3 billion to add SNV4818, a mutant‑selective PI3Kα inhibitor, to its oncology pipeline. The deal includes roughly two‑thirds of the consideration upfront and folds a program aimed at HR+/HER2‑ metastatic breast cancer into Novartis’ precision oncology strategy, the company said. Novartis highlighted preclinical data showing selectivity for PIK3CA mutant enzymes versus wild‑type, positioning SNV4818 to improve tolerability compared with prior PI3Kα inhibitors and enabling combinations with endocrine therapy. The program is in a Phase I/II trial (NCT06736704); Novartis’ Shreeram Aradhye framed the asset as an attempt to translate established biology into a more tolerable precision medicine.